[go: up one dir, main page]

AU8200191A - High efficiency packaging of mutant adeno-associated virus using amber suppressions - Google Patents

High efficiency packaging of mutant adeno-associated virus using amber suppressions

Info

Publication number
AU8200191A
AU8200191A AU82001/91A AU8200191A AU8200191A AU 8200191 A AU8200191 A AU 8200191A AU 82001/91 A AU82001/91 A AU 82001/91A AU 8200191 A AU8200191 A AU 8200191A AU 8200191 A AU8200191 A AU 8200191A
Authority
AU
Australia
Prior art keywords
high efficiency
associated virus
efficiency packaging
mutant adeno
suppressions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU82001/91A
Inventor
Barrie J. Carter
Nor Chejanovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Commerce
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of AU8200191A publication Critical patent/AU8200191A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU82001/91A 1990-07-09 1991-07-09 High efficiency packaging of mutant adeno-associated virus using amber suppressions Abandoned AU8200191A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54930490A 1990-07-09 1990-07-09
US549304 1990-07-09

Publications (1)

Publication Number Publication Date
AU8200191A true AU8200191A (en) 1992-02-04

Family

ID=24192449

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82001/91A Abandoned AU8200191A (en) 1990-07-09 1991-07-09 High efficiency packaging of mutant adeno-associated virus using amber suppressions

Country Status (2)

Country Link
AU (1) AU8200191A (en)
WO (1) WO1992001070A1 (en)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4339352A1 (en) * 1993-11-18 1995-05-24 Univ Ludwigs Albert Method for labeling cells, cells labeled with this method, use of the wild-type adeno-associated virus for labeling cells and test kits for detecting the wild-type adeno-associated virus in cells
CA2202664A1 (en) * 1994-10-13 1996-04-25 Christina Holscher Preparation of rep-negative aav mutants and cells which can be used therefor
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2000011154A1 (en) * 1998-08-20 2000-03-02 Cell Genesys, Inc. USE OF SUPPRESSOR tRNA'S TO REGULATE CYTOTOXICITY DURING THE PRODUCTION OF RECOMBINANT GENE PRODUCTS
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
US6410236B1 (en) 1999-09-01 2002-06-25 The Regents Of The University Of Michigan Correcting diastolic dysfunction in heart failure
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
WO2001062778A2 (en) 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
ATE499948T1 (en) 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic NUCLEIC ACID MUCOSAL IMMUNIZATION
JP2005504513A (en) 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of prostate cancer
JP4302513B2 (en) 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Polynucleotides encoding antigenic type B HIV polypeptides and / or antigenic type C HIV polypeptides, polypeptides thereof and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
AU2002362019B2 (en) 2001-11-21 2007-12-20 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
DK1581119T3 (en) 2001-12-17 2013-05-13 Corixa Corp Compositions and Methods for Therapy and Diagnosis of Inflammatory Bowel Diseases
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
EP2322186A3 (en) 2002-11-21 2011-07-13 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
KR101110889B1 (en) 2003-01-06 2012-02-20 코릭사 코포레이션 Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2525825A1 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
PL2277996T3 (en) 2003-05-21 2015-03-31 Genzyme Corp Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1789552A2 (en) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
WO2006020996A2 (en) 2004-08-11 2006-02-23 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
ATE511401T1 (en) 2004-08-12 2011-06-15 Cedars Sinai Medical Center COMBINED GENE THERAPY FOR THE TREATMENT OF MACROSCOPIC GLIOMA
AU2005287505A1 (en) 2004-09-22 2006-03-30 Biosynexus Incorporated Staphylococcal immunogenic compositions
DK1807009T3 (en) 2004-10-05 2015-03-02 Genzyme Corp Stair shaped needle
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1885863B1 (en) 2005-05-31 2014-11-19 The Regents of the University of Colorado, a body corporate Methods for delivering genes
US7858590B2 (en) 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
CA2648086C (en) 2006-03-29 2014-05-13 Dana Farber Cancer Institute, Inc. Methods and compositions for inducing an immune response to hiv and models for testing
US8685720B2 (en) 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
ES2872337T3 (en) 2008-06-25 2021-11-02 Mesoblast Inc STRO-1bright cells for use in the treatment of low back pain
ES2550795T3 (en) 2008-11-20 2015-11-12 Mesoblast, Inc. Method to treat or prevent pancreatic dysfunction
BRPI1005670A8 (en) 2009-01-05 2017-12-26 Epitogenesis Inc adjuvant compositions and processes of use.
AU2010208058A1 (en) 2009-01-29 2011-08-18 University Of California, San Francisco Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
CN107083400A (en) 2009-05-02 2017-08-22 建新公司 The gene therapy of nerve degenerative diseases
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
KR101891260B1 (en) 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. Treatment of t-cell mediated immune disorders
WO2012049314A1 (en) 2010-10-15 2012-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24 -hydrolase in therapy of huntington' s disease
CN112891374B (en) 2011-06-03 2024-12-27 麦瑟布莱斯特公司 Ways to treat the effects of a stroke
MX2013013627A (en) 2011-06-21 2014-04-25 Oncofactor Corp COMPOSITIONS AND METHODS FOR CANCER THERAPY AND DIAGNOSIS.
JP6499446B2 (en) 2011-06-24 2019-04-10 エピットジェネシス・インコーポレーテッド Pharmaceutical composition containing a combination of a selective carrier, vitamin, tannin and flavonoid as an antigen-specific immune modulator
SG195170A1 (en) 2011-07-04 2013-12-30 Mesoblast Inc Methods of treating or preventing rheumatic disease
WO2013033777A1 (en) 2011-09-09 2013-03-14 Mesoblast, Inc Methods for increasing osteoblastic function
AU2013360024B2 (en) 2012-12-12 2019-02-28 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
CA2897444A1 (en) 2013-01-08 2014-07-17 Genzyme Corporation Use of inos inhibitors to increase viral yield in culture
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
CN105229023B (en) 2013-03-15 2019-08-16 加利福尼亚大学董事会 The mitochondrial-derived peptide MOTS3 regulates metabolism and cell survival
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
US9644215B2 (en) 2013-04-12 2017-05-09 The General Hospital Corporation AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
WO2015067668A1 (en) 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) New alzheimer's disease animal model
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201606101WA (en) 2014-02-06 2016-08-30 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
WO2015124546A1 (en) 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
WO2015143177A1 (en) 2014-03-21 2015-09-24 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
JP6956635B2 (en) 2014-12-17 2021-11-02 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
DK3233130T3 (en) 2014-12-17 2021-06-21 Fundacion Para La Investig Medica Aplicada NUCLEIC ACID CONSTRUCTIONS AND GENERATIVE VECTORS FOR USE IN THE TREATMENT OF WILSON DISEASE
EP3054006A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
WO2016150964A1 (en) 2015-03-23 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
AU2016235163B2 (en) 2015-03-24 2022-03-24 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
CN107771220B (en) 2015-05-05 2022-07-05 迈索布拉斯特国际有限公司 Efficacy analysis
ES2959642T3 (en) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services METHODS AND COMPOSITIONS TO INDUCE AN IMMUNE RESPONSE THROUGH CONSTRUCTIONS WITH CONSERVED ELEMENTS
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3307391A1 (en) 2015-06-12 2018-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
ES2895652T3 (en) 2015-07-07 2022-02-22 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
WO2017096164A1 (en) 2015-12-02 2017-06-08 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
PL3405215T3 (en) 2016-01-19 2022-10-31 The Regents Of The University Of California METHODS OF TREATMENT FOR DANON'S DISEASE AND OTHER AUTOPHAGY DISORDERS
AU2017219865B2 (en) 2016-02-16 2023-04-13 The Board Of Trustees Of The Leland Stanford Junior University Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
PT3436051T (en) 2016-03-31 2021-11-02 Spark Therapeutics Inc FULLY SCALABLE COLUMN BASED RAAV MANUFACTURING PROCESS
NZ749593A (en) 2016-06-20 2025-10-31 Univ Leland Stanford Junior Circular rnas and their use in immunomodulation
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US12178845B2 (en) 2016-12-07 2024-12-31 The General Hospital Corporation Methods and compositions relating to the treatment of tumors
WO2018138360A1 (en) 2017-01-28 2018-08-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Oxygen carrying blood substitutes and their use as delivery vehicles
FI3574091T3 (en) 2017-01-30 2023-05-03 Brainvectis Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
EP3600267A1 (en) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of neurodegenerative disease
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
CA3062112A1 (en) 2017-05-04 2018-11-08 Mesoblast International Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
US12416015B2 (en) 2017-09-15 2025-09-16 The Board Of Trustees Of The Leland Stanford Junior University Multiplex production and barcoding of genetically engineered cells
WO2019144186A1 (en) 2018-01-23 2019-08-01 Southern Eye Equipment Expression vector and method
EP3765065A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175381A1 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
US12098179B2 (en) 2018-03-16 2024-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
US11608510B2 (en) 2018-03-30 2023-03-21 The Board Of Trustees Of The Leland Stanford Junior University Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
RU2020134965A (en) 2018-04-27 2022-04-27 Спейскрафт Севен, Ллк GENE THERAPY FOR CNS DEGENERATION
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
JP7586810B2 (en) 2018-07-12 2024-11-19 ロケット ファーマシューティカルズ リミテッド Gene therapy vector for the treatment of Danon disease
AU2019356165A1 (en) 2018-10-12 2021-05-27 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (PFIC3)
CA3118163A1 (en) 2018-10-29 2020-05-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
JP2022512930A (en) 2018-11-07 2022-02-07 ヴィヴェ テラピューティクス Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
MX2021006241A (en) 2018-12-04 2021-08-11 Catalent Pharma Solutions Llc Vectors for protein manufacture.
BR112021013158A2 (en) 2019-01-02 2021-09-14 Mesoblast International Sàrl METHOD TO TREAT LUMBAR PAIN
EP3906036A1 (en) 2019-01-03 2021-11-10 Mesoblast International Sàrl Method for improving visual acuity
WO2020193441A1 (en) 2019-03-22 2020-10-01 Université de Paris New inhibitors of lrrk2/pp1 interaction
WO2020234363A2 (en) 2019-05-21 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
WO2020234450A1 (en) 2019-05-23 2020-11-26 Mesoblast International Sarl Functional recovery from cerebral infarction
CA3145446A1 (en) 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof
EP3997225A1 (en) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
WO2021076634A1 (en) * 2019-10-15 2021-04-22 University Of Massachusetts Aav production strategy using a cell line expressing an inducible rep gene
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
EP4100539B1 (en) 2020-04-27 2025-11-19 4D Molecular Therapeutics Inc. Adeno-associated variants, formulations and methods for pulmonary delivery
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CA3185503A1 (en) 2020-06-09 2021-12-16 Genethon Nrf2 activator for use in treating dilated cardiomyopathies
EP4162049A1 (en) 2020-06-09 2023-04-12 Genethon Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
US20230265427A1 (en) 2020-06-09 2023-08-24 Genethon Treatment of Genetic Dilated Cardiomyopathies
US20240018524A1 (en) 2020-07-10 2024-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating epilepsy
CA3181024A1 (en) 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
KR20230043869A (en) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Placophilin-2 (PKP2) gene therapy using AAV vectors
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CN116323941A (en) 2020-09-29 2023-06-23 吉尼松公司 Enhancement of dystrophin-related protein expression in cells by inducing mutations within dystrophin-related protein regulatory elements and therapeutic use thereof
CN116390935A (en) 2020-10-09 2023-07-04 Ucb生物制药有限责任公司 Nucleic acid construct, viral vector and viral particle
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
US20240091382A1 (en) 2020-12-23 2024-03-21 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
US20250084420A1 (en) 2021-08-02 2025-03-13 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4419684A1 (en) 2021-10-21 2024-08-28 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Retroelement-generated transcription factor decoys
WO2023073071A1 (en) 2021-10-28 2023-05-04 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4472674A1 (en) 2022-02-01 2024-12-11 Cornell University Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia
EP4499839A1 (en) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
KR20250035544A (en) 2022-07-08 2025-03-12 코넬 유니버시티 Methods and pharmaceutical compositions for the treatment and prevention of Alzheimer's disease
WO2024020346A2 (en) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Gene editing components, systems, and methods of use
EP4558149A1 (en) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024079317A1 (en) 2022-10-14 2024-04-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies
CN120752339A (en) 2023-01-06 2025-10-03 国家医疗保健研究所 Intravenous administration of antisense oligonucleotides for the treatment of pain
WO2024175604A1 (en) 2023-02-21 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
WO2024220719A1 (en) 2023-04-18 2024-10-24 Crystal Ronald G Modified aav capsids for gene delivery
WO2024220722A1 (en) 2023-04-18 2024-10-24 Cornell University Compositions and methods for tissue- specific expression of gene therapies
WO2024220726A1 (en) 2023-04-18 2024-10-24 Cornell University Methods and apoe pharmaceutical compositions for the treatment and the prevention of alzheimers disease
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025051758A1 (en) 2023-09-04 2025-03-13 Splicebio, Sl Use of split intein for the treatment of scn1a associated disease
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
EP4563586A1 (en) 2023-11-28 2025-06-04 Université Paris Cité New inhibitors of lrrk2/pp1 interaction
WO2025114512A1 (en) 2023-11-29 2025-06-05 Cnrs Dsi Therapeutic use of surf2 modulators
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2026013288A1 (en) 2024-07-12 2026-01-15 Splicebio, Sl Split intein for use in the treatment of cep290-associated disease

Also Published As

Publication number Publication date
WO1992001070A1 (en) 1992-01-23

Similar Documents

Publication Publication Date Title
AU8200191A (en) High efficiency packaging of mutant adeno-associated virus using amber suppressions
AU3434393A (en) Targeted virus
AU8028491A (en) Integrally belted absorbent products
AU550147B2 (en) Thymidinekinase-removed pseudorabies virus
AU8097291A (en) Surround processor
AU640629B2 (en) Unit dose package
AU8031191A (en) Package
AU2886495A (en) Cyclonic reactor
AU2616192A (en) Perfume particles
AU2616292A (en) Perfume particles
AU5926794A (en) Medicament pack
AU2526797A (en) Stimulation of immune response with low doses of interleukin-2
AU560366B2 (en) Inactivation of a lipid virus
AU578170B2 (en) Dual-type damper
AU1502992A (en) Detection of viruses
AU5836390A (en) Human lymphoma-associated virus
AU4156989A (en) Leukotriene antagonist prodrugs
AU630186B2 (en) Canine corona virus vaccine
AU8531291A (en) Bowl package
AU3005392A (en) Centrifugal separator
AU7104194A (en) High yielding influenza viruses
AU4215189A (en) Charged particle multidetector
AU1820692A (en) Novel anti-hiv antibodies
AU7892491A (en) Pfbc power plant
AU7881191A (en) Improvements relating to packaging of potatoes